Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sanakin BioScience has developed and commercialized the "Sanakin Technology," which enables the production of an autologous cytokine-rich serum from a patient's own blood. This technology is used for regulating inflammation and stimulating tissue regeneration in both human medicine (orthopedics, dermatology) and veterinary medicine. The company reports over 300,000 applications worldwide with more than 1,600 doctors using their therapies across 40+ countries as of 2022. Clinical results are described as encouraging in terms of safety/tolerability and efficacy for reducing inflammation and promoting healing/regeneration.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Sanakin BioScience.